What is the share price of Wyeth Ltd.- (Amalgamated) (WYETH)?

Company share prices are keep on changing according to the market conditions. The current trading price of Wyeth Ltd.- (Amalgamated) (WYETH) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the P/E ratio of Wyeth .- (Amalgamated)?

The latest standalone P/E ratio of Wyeth .- (Amalgamated) as of 01-Jan-1970 is 27.72.

What is the P/B ratio of Wyeth Ltd.- (Amalgamated) (WYETH)?

The latest standalone P/B ratio of Wyeth Ltd.- (Amalgamated) (WYETH) as of 01-Jan-1970 is 9.15.

What is the 52-week high and low of Wyeth Ltd.- (Amalgamated) (WYETH)?

The 52-week high of Wyeth Ltd.- (Amalgamated) (WYETH) is Rs. 1395.90 and the 52-week low is Rs. 1330.25.

Wyeth Ltd.- (Amalgamated) (WYETH) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Wyeth Ltd.- (Amalgamated) (WYETH)
Brand: Wyeth .- (Amalgamated)

Wyeth Ltd.- (Amalgamated) (WYETH)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500095 NSE: WYETH Pharmaceuticals & Drugs | Small Cap | Wyeth Share Price

Wyeth Ltd.- (Amalgamated) (WYETH)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500095 NSE: WYETH Pharmaceuticals & Drugs | Small Cap | Wyeth Share Price

Key Metrics

Valuation Multiples

Market Cap

₹3,032 Cr.

Current Price

₹0

52-Week Low / High

₹1,330 / 1,396

TTM EPS

₹48.1

TTM Sales

₹735 Cr.

Book Value per Share

₹145.8

P/E Ratio

27.72

Industry PE

46.6

Price to Book (P/B)

9.15

Price to Sales (P/S)

4.13

EV/EBITDA

16.96

Dividend Yield

16.29%

Profitability Efficiency

Return on Equity (ROE)

21.03%

Return on Capital Employed (ROCE)

31.94%

Return on Assets (ROA)

13.92%

Operating Profit Margin

17.4%

Net Profit Margin

12.94%

Gross Profit Margin

19.5%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

0.15%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-36.73%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

-32.4%

Asset Quality

Promoter Holding

51.12%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹309 Cr.

Equity

₹22.7 Cr.

Face Value

₹10

All Time Low / High

₹171.00 / 1409.00

Wyeth .- (Amalgamated) stock performance

Key Ratios

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Nov'09	Mar'11	Mar'12	Mar'13	Mar'14	TTM
ROCE % ⓘ	18.5%	34.1%	44%	45.4%	53.4%	29.6%	71%	47.2%	36.9%	31.9%	-
Growth Parameters ⓘ
Sales ⓘ	256	287	288	331	383	430	481	589	678	679	735
Sales YoY Gr.	-	12.4%	0.3%	15%	15.5%	12.3%	12%	22.4%	15.3%	0.2%	-
Adj EPS ⓘ	17.6	26.5	39.8	35.9	45.1	38.7	54.6	64.4	58.7	43.6	48.1
YoY Gr.	-	50.3%	50.4%	-10%	25.8%	-14.3%	41.1%	18%	-8.9%	-25.8%	-
BVPS (₹) ⓘ	106.7	108	113	113.7	119.6	183.2	127	212.1	249.5	118.5	145.8
Adj Net Profit ⓘ	40.1	60.2	90.5	81.5	102	87.8	124	146	133	99	109
Cash Flow from Ops. ⓘ	29.4	60.5	79	85.8	60.2	86.6	113	76.4	92.3	119	-
Debt/CF from Ops. ⓘ	0.1	0	0	0	0	0	0	0	0	0	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	11.5%	12.2%	12.2%	0.2%
Adj EPS ⓘ	10.6%	-0.7%	-7.2%	-25.8%
BVPSⓘ	1.2%	-0.2%	-2.3%	-52.5%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Nov'09	Mar'11	Mar'12	Mar'13	Mar'14	TTM
Return on Equity % ⓘ	16.1	24.7	36.1	31.6	38.7	21.3	49.9	33.8	25.4	23.7	36.4
Op. Profit Mgn % ⓘ	5	24.4	34.7	31.9	34.5	27.8	35.2	31.5	24.5	17.4	19.5
Net Profit Mgn % ⓘ	15.7	21	31.4	24.6	26.8	20.5	25.8	24.9	19.7	14.6	14.9
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	0
Working Cap Days ⓘ	170	137	129	115	126	200	97	134	148	161	103
Cash Conv. Cycle ⓘ	31	-2	22	10	-2	5	-4	11	14	-44	51

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Nov'09	Mar'11	Mar'12	Mar'13	Mar'14
Sales	255.50	287.29	288.13	331.32	382.65	286.36	641.26	588.53	678.34	679.33
Operating Expenses ⓘ +	244.83	217.66	188.04	225.75	254.63	207.75	415.25	410.75	516.62	577.01
Manufacturing Costs	37.45	35.61	34.28	36.61	38.92	28.58	55.13	47.74	28.42	27.15
Material Costs	68.17	82.21	75.42	92.41	102.12	85.58	193.14	194.95	255.91	309.10
Employee Cost	84.26	40.45	35.51	37.82	43.12	36.31	55.24	38.19	40.50	35.85
Other Costs ⓘ	54.95	59.38	42.83	58.91	70.47	57.28	111.73	129.87	191.79	204.91
Operating Profit ⓘ	10.67	69.63	100.09	105.57	128.02	78.61	226.01	177.78	161.72	102.32
Operating Profit Margin (%)	4.2%	24.2%	34.7%	31.9%	33.5%	27.4%	35.2%	30.2%	23.8%	15.1%
Other Income ⓘ +	43.24	20.68	17.58	19.04	21.58	10.15	19.91	33.98	35.26	34.74
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.39	0.28	0.35	0.39	0.40	0.28	1.25	0.96	1.05	0.44
Depreciation ⓘ	7.48	6.16	6.21	6.47	6.85	6.76	8.99	5.88	2.66	2.74
Profit Before Tax ⓘ	46.04	83.87	111.11	117.76	142.36	81.72	235.68	204.92	193.27	133.88
Tax ⓘ	7.04	16.15	18.75	36.28	42.69	22.71	70.38	60.22	63.22	45.96
Profit After Tax	39	67.72	92.36	81.48	99.67	59.01	165.29	144.69	130.06	87.92
PAT Margin (%)	15.3%	23.6%	32.1%	24.6%	26.1%	20.6%	25.8%	24.6%	19.2%	12.9%
Adjusted EPS (₹)	17.2	29.8	40.7	35.9	43.9	26.0	72.8	63.7	57.2	38.7
Dividend Payout Ratio (%)	116.50%	83.90%	73.80%	83.70%	74.10%	77%	30.20%	28.30%	29.70%	374.70%

Valuation of Wyeth - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Nov'09	Mar'11	Mar'12	Mar'13	Mar'14
Equity and Liabilities
Shareholders Fund +	242.48	245.44	256.66	258.40	271.68	277.52	384.77	481.93	566.80	269.29
Share Capital ⓘ	22.72	22.72	22.72	22.72	22.72	22.72	22.72	22.72	22.72	22.72
Reserves ⓘ	219.76	222.72	233.94	235.68	248.96	254.80	362.05	459.21	544.08	246.57
Debt +	2.50	2.50	2.50	2.50	2.50	2.50	2.50	2.50	2.50	2.50
Long Term Debt	2.50	2.50	2.50	2.50	2.50	2.50	2.50	2.50	2.50	2.50
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	48.70	25.06	24.33	34.06	51.99	44.82	63.44	80.77	140.15	180.12
Others Liabilities ⓘ	51.12	66.69	86.35	90.48	100.49	72.31	42.06	77.98	69.59	32.28
Total Liabilities ⓘ	344.81	339.69	369.85	385.45	426.66	397.16	492.77	643.18	779.04	484.19
Fixed Assets
Net Fixed Assets ⓘ +	53.90	47.23	43.35	39.12	38.20	31.92	25.60	23.89	24.15	24.12
Gross Block	89.63	76.54	75.54	76.80	80.54	80.77	79.77	82.64	83.93	84.77
Accumulated Depreciation	35.73	29.31	32.19	37.68	42.34	48.85	54.17	58.74	59.79	60.65
CWIP ⓘ	0.53	0.50	0.68	2.81	0.67	1.65	1.51	1.81	0.28	0.43
Investments ⓘ	0.24	0.24	0.24	0.24	0	0	0	0	0	0
Inventories	48.35	43.74	46.24	39.52	55.99	59.69	74.62	119.98	184.46	159.32
Trade Receivables	13.85	19.54	19.27	22.37	24.50	19.50	34.08	54.48	44.49	50.02
Cash Equivalents ⓘ	163.75	183.43	211.17	229.62	223.96	205.52	274.45	363.39	439.30	157.22
Others Assets ⓘ	64.19	45.02	48.90	51.77	83.34	78.87	82.50	79.62	86.37	93.08
Total Assets ⓘ	344.81	339.69	369.85	385.45	426.66	397.16	492.77	643.18	779.04	484.19

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Nov'09	Mar'11	Mar'12	Mar'13	Mar'14
Cash Flow From Operating Activity ⓘ +	29.44	60.53	79.01	85.84	60.24	57.75	151	76.44	92.32	118.83
PBT ⓘ	46.04	83.87	111.11	117.76	142.36	81.72	235.68	204.92	193.27	133.88
Adjustment ⓘ	-31.09	-6.90	-9.89	-10.59	-12.55	0.10	-10.77	-27.23	-14.94	-24.24
Changes in Working Capital ⓘ	36.91	-12.72	-3.35	9.46	-22.52	-8.24	-11.14	-37.28	-11.93	58.43
Tax Paid ⓘ	-22.42	-3.72	-18.85	-30.79	-47.04	-15.83	-62.76	-63.97	-74.08	-49.25
Cash Flow From Investing Activity ⓘ +	49.21	11.15	13.72	12.59	14.15	10.06	11.53	31.26	31.69	28.69
Capex	-3.14	3.65	-0.70	-4.55	-3.63	-1.43	-5.75	2.47	-0.71	-2.35
Net Investments	0	0	0	0	0.31	0	0	0	0	0
Others ⓘ	52.36	7.49	14.43	17.14	17.47	11.49	17.28	28.79	32.40	31.04
Cash Flow From Financing Activity ⓘ +	-26.20	-51.99	-65	-79.98	-80.05	-86.25	-93.61	-18.77	-48.10	-429.59
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-0.54	-0.30	-0.35	-0.39	-0.40	-0	-0.87	-0.33	-0.59	-0.11
Dividend Paid ⓘ	-22.69	-45.32	-56.68	-68.01	-68.07	-73.69	-79.53	-18.44	-40.87	-366.93
Others ⓘ	-2.97	-6.37	-7.97	-11.58	-11.58	-12.55	-13.21	0	-6.63	-62.55
Net Cash Flow ⓘ	52.45	19.68	27.74	18.45	-5.66	-18.44	68.93	88.94	75.91	-282.08

Financial Ratio

PARTICULARS	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Nov'09	Mar'11	Mar'12	Mar'13	Mar'14
Ratios
ROE (%)	15.67	27.76	36.79	31.64	37.61	21.49	49.92	33.39	24.8	21.03
ROCE (%)	18.47	34.14	43.96	45.43	53.36	29.59	71.01	47.24	36.88	31.94
Asset Turnover Ratio	0.86	0.92	0.89	0.96	0.99	0.71	1.48	1.07	0.99	1.11
PAT to CFO Conversion(x)	0.75	0.89	0.86	1.05	0.6	0.98	0.91	0.53	0.71	1.35
Working Capital Days
Receivable Days	26.90	19.30	22.40	21	21.30	27.30	14.90	26.70	25.80	24.60
Inventory Days	72.60	53.30	51.90	43.30	43.40	71.70	37.30	58.70	79.20	89.50
Payable Days	205	163.80	119.50	115.30	153.80	206.40	102.30	135	157.60	189.10

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Wyeth Ltd.- (Amalgamated) FAQs

The current trading price of Wyeth on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Wyeth stood at ₹3,032.2 Cr

The latest P/E ratio of Wyeth as of 31-Dec-1969 is 27.72.

The latest P/B ratio of Wyeth as of 31-Dec-1969 is 9.15.

The 52-week high of Wyeth is ₹1,395.9 and the 52-week low is ₹1,330.3.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Wyeth is ₹735 ( Cr.) .

Data is not available for this company.

No data found

About Wyeth Ltd.- (Amalgamated)

Wyeth Limited (Wyeth) the Indian subsidiary of US-based Pharma Company Wyeth and now a Pfizer group company, is a global leader in pharmaceutical, consumer healthcare and animal health products. It was established in 1947 as a private limited company under the name Lederle Laboratories (India) Ltd. In 1962, the name was changed to Cyanamid India Ltd. The company became a public enterprise in 1965. In 1998, three companies - Wyeth Laboratories, John Wyeth India and Wyeth India (Pvt) Ltd -- were transferred to the company and its name was changed to Wyeth Lederle Ltd. In 2003, Geoffrey Manners & Co Ltd was merged and the name of the company was changed to Wyeth Ltd.

The pharmaceuticals business of the company comprises bulk drugs and formulations, such as oral contraceptives, hormone replacement therapy, antibiotics, vaccines, steroids and other prescription medicines. The company also manufactures OTC pharmaceuticals, cosmetics, toiletries and other allied consumer products. It has a manufacturing facility in Goa. The company was a pioneer, introducing several new therapies such as hormone therapy, in India. In the field of vaccines, the company introduced vaccines against HIB and invasive pneumococcal disease.

It has launched several products that are known internationally such as Enbrel-for treatment for rheumatoid arthritis, Rapamune- an immuno suppressant for prevention of rejection after renal transplant and Prevenar- a pneumococcal conjugate vaccine. The company launched the world's first glycilcycline antibiotic, Tygacil. Wyeth manufactures drugs in areas of antibiotics, steroids, vaccines, cardiovascular system, vitamins and hematinics, central nervous system and immunology.

On November 23, 2013, the Board of Directors of Pfizer India and Wyeth India at their meetings approved a proposal to merge Wyeth India with Pfizer India. The appointed date for the merger was April 1, 2013, the swap ratio, post interim dividend for the merger was 7 shares of Pfizer India (face value of Rs 10 each), for every 10 shares of Wyeth India (face value of Rs 10 each)

Milestones

Acquisition of Wyeth, USA by Pfizer Inc

In 2009, Wyeth of USA merged with Wagner Acquisition Corp, a direct, wholly-owned subsidiary of Pfizer Inc. As a result of the merger, Pfizer Inc is now the parent company of Wyeth and hence the ultimate parent of the Indian company. Pfizer acquired Wyeth for $68 billion in order to diversify its product portfolio, which includes Wyeth's major biotech drugs and vaccines. In India, Pfizer Ltd and Wyeth Ltd continue as two separate entities.

FY09: Strong performance from key products; new product launches

In the period ended November 30, 2009 Wyeth continued to maintain its leadership position in oral contraceptives, hormone therapy and folic acid markets. Two key products saw strong growth -- Enbrel, a breakthrough treatment for rheumatoid arthritis and psoriasis, achieved growth of 38%, while Prevenar, a vaccine for invasive pneumococcal disease, achieved growth of 75%. An applicator â€œAnne French roll-onâ€ with additional features attracted new consumers. The newly launched Anacin Multi-Pain has broadened the brandâ€™s relevance for consumers by targeting more usage occasions than before.

FY09: Strong performance from key products; new product launches

Wyeth exports pharmaceutical and healthcare products predominantly to the USA, Europe and Japan. As of November 2009, exports accounted for 30% of its total turnover.

Wyeth Ltd.- (Amalgamated) (WYETH)

Wyeth Ltd.- (Amalgamated) (WYETH)

Wyeth .- (Amalgamated) stock performance

10 Year X-Ray :